Two obesity drugs can push the same brain receptor in opposite directions and still lead to weight loss. A newer generation of weight loss medications targets receptors that influence appetite and blood sugar control. Some medications also act on the glucose-dependent insulinotropic polypeptide receptor (GIPR). The findings also indicated that both approaches can increase weight loss when paired with certain GLP-1-based medications. They may also help researchers design more effective combinations of weight loss drugs.